MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma | MicrobiomeTrials← Back to trialsNCT06097728
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2023-11-09Est. Completion: 2028-11-16
Enrollment target: 861 participants Locations- Research Site, Santa Rosa, California, United States
- Research Site, Aurora, Colorado, United States
- Research Site, Jacksonville, Florida, United States
- Research Site, Atlanta, Georgia, United States
- Research Site, Chicago, Illinois, United States
- Research Site, Rochester, Minnesota, United States
- Research Site, St Louis, Missouri, United States
- Research Site, Commack, New York, United States
- Research Site, Columbus, Ohio, United States
- Research Site, Portland, Oregon, United States
- Research Site, Portland, Oregon, United States
- Research Site, Philadelphia, Pennsylvania, United States
- Research Site, Houston, Texas, United States
- Research Site, Fairfax, Virginia, United States
- Research Site, Chermside, Australia
- Research Site, Clayton, Australia
- Research Site, Melbourne, Australia
- Research Site, Nedlands, Australia
- Research Site, Westmead, Australia
Other microbiome trials you might be interested in
ThymomaStomach NeoplasmsPancreatic NeoplasmsMesotheliomaBiliary Tract NeoplasmsMesothelin Expressing Neoplasms
Background:
* Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, peri…
Bethesda, United StatesEst. completion Jul 25, 2033
Mesothelin-Expressing TumorsEpithelial Ovarian CancerMalignant Pleural Mesothelioma, AdvancedMalignant Peritoneal Mesothelioma, Advanced
Research Site, Anderlecht, BelgiumResearch Site, Antwerp, BelgiumResearch Site, Ghent, BelgiumResearch Site, Hasselt, BelgiumResearch Site, Sint-Niklaas, BelgiumResearch Site, Barretos, BrazilResearch Site, Fortaleza, BrazilResearch Site, Porto Alegre, BrazilResearch Site, Rio de Janeiro, BrazilResearch Site, Santo André, BrazilResearch Site, São Paulo, BrazilResearch Site, Edmonton, Alberta, CanadaResearch Site, Ottawa, Ontario, CanadaResearch Site, Toronto, Ontario, CanadaResearch Site, Montreal, Quebec, CanadaResearch Site, Québec, Quebec, CanadaResearch Site, Beijing, ChinaResearch Site, Beijing, ChinaResearch Site, Changsha, ChinaResearch Site, Chengdu, ChinaResearch Site, Guangzhou, ChinaResearch Site, Hangzhou, ChinaResearch Site, Harbin, ChinaResearch Site, Kunming, ChinaResearch Site, Lanzhou, ChinaResearch Site, Ningbo, ChinaResearch Site, Qingdao, ChinaResearch Site, Shandong, ChinaResearch Site, Shanghai, ChinaResearch Site, Shenyang, ChinaResearch Site, Taiyuan, ChinaResearch Site, Taiyuan, ChinaResearch Site, Tianjin, ChinaResearch Site, Tianjin, ChinaResearch Site, Wuhan, ChinaResearch Site, Xi'an, ChinaResearch Site, Zhengzhou, ChinaResearch Site, Zhengzhou, ChinaResearch Site, Aarhus N, DenmarkResearch Site, Copenhagen, DenmarkResearch Site, Brest, FranceResearch Site, Créteil, FranceResearch Site, Le Mans, FranceResearch Site, Lille, FranceResearch Site, Lyon, FranceResearch Site, Marseille, FranceResearch Site, Montpellier, FranceResearch Site, Paris, FranceResearch Site, Rouen, FranceResearch Site, Saint-Herblain, FranceResearch Site, Strasbourg, FranceResearch Site, Toulouse, FranceResearch Site, Berlin, GermanyResearch Site, Berlin, GermanyResearch Site, Bochum, GermanyResearch Site, Cologne, GermanyResearch Site, Essen, GermanyResearch Site, Gauting, GermanyResearch Site, Georgsmarienhütte, GermanyResearch Site, Großhansdorf, GermanyResearch Site, Hamburg, GermanyResearch Site, Heidelberg, GermanyResearch Site, Kiel, GermanyResearch Site, Münster, GermanyResearch Site, Regensburg, GermanyResearch Site, Alessandria, ItalyResearch Site, Bari, ItalyResearch Site, Bergamo, ItalyResearch Site, Milan, ItalyResearch Site, Monza, ItalyResearch Site, Orbassano, ItalyResearch Site, Padova, ItalyResearch Site, Parma, ItalyResearch Site, Rozzano, ItalyResearch Site, Varese, ItalyResearch Site, Amagasaki-shi, JapanResearch Site, Hakodate-shi, JapanResearch Site, Hiroshima, JapanResearch Site, Kitaadachi-gun, JapanResearch Site, Kitakyushu-shi, JapanResearch Site, Matsuyama, JapanResearch Site, Nagoya, JapanResearch Site, Nishinomiya-shi, JapanResearch Site, Okayama, JapanResearch Site, Osakasayama-shi, JapanResearch Site, Tokyo, JapanResearch Site, Ube-shi, JapanResearch Site, Amsterdam, NetherlandsResearch Site, Eindhoven, NetherlandsResearch Site, Rotterdam, NetherlandsResearch Site, Lørenskog, NorwayResearch Site, Oslo, NorwayResearch Site, Bystra, PolandResearch Site, Olsztyn, PolandResearch Site, Poznan, PolandResearch Site, Warsaw, PolandResearch Site, Cape Town, South AfricaResearch Site, eManzimtoti, South AfricaResearch Site, Johannesburg, South AfricaResearch Site, Johannesburg, South AfricaResearch Site, Kimberly, South AfricaResearch Site, Pretoria, South AfricaResearch Site, Pretoria, South AfricaResearch Site, Seoul, South KoreaResearch Site, Seoul, South KoreaResearch Site, Seoul, South KoreaResearch Site, Barakaldo, SpainResearch Site, Barcelona, SpainResearch Site, Madrid, SpainResearch Site, Oviedo, SpainResearch Site, Baden, SwitzerlandResearch Site, Basel, SwitzerlandResearch Site, Bern, SwitzerlandResearch Site, Fribourg, SwitzerlandResearch Site, Sankt Gallen, SwitzerlandResearch Site, Kaohsiung City, TaiwanResearch Site, Taichung, TaiwanResearch Site, Taipei, TaiwanResearch Site, Ankara, Turkey (Türkiye)Research Site, Ankara, Turkey (Türkiye)Research Site, Diyarbakır, Turkey (Türkiye)Research Site, Izmir, Turkey (Türkiye)Research Site, Cambridge, United KingdomResearch Site, Leeds, United KingdomResearch Site, Leicester, United KingdomResearch Site, London, United KingdomResearch Site, London, United KingdomResearch Site, London, United KingdomResearch Site, Manchester, United KingdomResearch Site, Newcastle upon Tyne, United KingdomResearch Site, Portsmouth, United KingdomResearch Site, Taunton, United KingdomPancreatic Adenocarcinoma Advanced or Metastatic
Lung Adenocarcinoma Metastatic
Cholangiocarcinoma Advanced
Cholangiocarcinoma Non-resectable
Mesothelin-expressing Advanced Cancers
Mesothelin-positive Advanced Malignant Solid Tumors
Colorectal Cancer
This is a Phase 1a/1b open-label, dose escalation study to evaluate the safety and efficacy of CT-95 (study drug), a hum…
Denver, United StatesEst. completion Dec 2026